Kyntra Bio reports Q1 2026 net loss of $15.1M ($3.74/share) and cash runway into 2028

KYNTRA BIO, INC.

2026-Q1 EPS reported -$3.76 vs consensus -$3.42 ▼ miss (-9.9%)

Phase 2 trial of FG-3246 in mCRPC enrolling; interim analysis expected in 4Q 2026.
Positive combo data with enzalutamide: median rPFS 7.0 mo overall, 10.1 mo in 1 prior ARPI.
Pivotal Phase 3 protocol for roxadustat in LR-MDS being finalized after FDA feedback; trial start H2 2026.
Revenue $3.7M (up from $2.7M); net loss $15.1M vs $16.8M YoY.
Cash and equivalents $100.3M; sufficient to fund operations into 2028.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001193125-26-216731

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.